RHOFADE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rhofade, and when can generic versions of Rhofade launch?
Rhofade is a drug marketed by Epi Hlth and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.
This drug has twenty-three patent family members in twelve countries.
The generic ingredient in RHOFADE is oxymetazoline hydrochloride. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the oxymetazoline hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Rhofade
There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for RHOFADE
International Patents: | 23 |
US Patents: | 7 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 62 |
Clinical Trials: | 4 |
Patent Applications: | 2,254 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for RHOFADE |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for RHOFADE |
What excipients (inactive ingredients) are in RHOFADE? | RHOFADE excipients list |
DailyMed Link: | RHOFADE at DailyMed |


Recent Clinical Trials for RHOFADE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Teva Pharmaceuticals USA | Phase 3 |
Actavis Inc. | Phase 3 |
Candela Corporation | Phase 4 |
Pharmacology for RHOFADE
Drug Class | Vasoconstrictor |
Physiological Effect | Increased Sympathetic Activity Vasoconstriction |
Anatomical Therapeutic Chemical (ATC) Classes for RHOFADE
Paragraph IV (Patent) Challenges for RHOFADE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
RHOFADE | Topical Cream | oxymetazoline hydrochloride | 1% | 208552 | 1 | 2019-06-20 |
US Patents and Regulatory Information for RHOFADE
RHOFADE is protected by seven US patents.
Patents protecting RHOFADE
Stabilized oxymetazoline formulations and their uses
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM, WHERE THE PATIENT EXPERIENCES NO REBOUND OR WORSENING OF FACIAL ERYTHEMA POST-TREATMENT
Stabilized oxymetazoline formulations and their uses
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS
Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using .alpha..sub.1-adrenoceptor agonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM
Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using .alpha..sub.1-adrenoceptor agonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM
Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using .alpha..sub.1-adrenoceptor agonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM
Pharmaceutical cream compositions and methods of use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Stabilized oxymetazoline formulations and their uses
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Epi Hlth | RHOFADE | oxymetazoline hydrochloride | CREAM;TOPICAL | 208552-001 | Jan 18, 2017 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Epi Hlth | RHOFADE | oxymetazoline hydrochloride | CREAM;TOPICAL | 208552-001 | Jan 18, 2017 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Epi Hlth | RHOFADE | oxymetazoline hydrochloride | CREAM;TOPICAL | 208552-001 | Jan 18, 2017 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Epi Hlth | RHOFADE | oxymetazoline hydrochloride | CREAM;TOPICAL | 208552-001 | Jan 18, 2017 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Epi Hlth | RHOFADE | oxymetazoline hydrochloride | CREAM;TOPICAL | 208552-001 | Jan 18, 2017 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Epi Hlth | RHOFADE | oxymetazoline hydrochloride | CREAM;TOPICAL | 208552-001 | Jan 18, 2017 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for RHOFADE
See the table below for patents covering RHOFADE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2014505026 | See Plans and Pricing | |
Australia | 2016238909 | Pharmaceutical cream compositions comprising oxymetazoline | See Plans and Pricing |
Portugal | 2645993 | See Plans and Pricing | |
Denmark | 2645993 | See Plans and Pricing | |
Canada | 2819633 | COMPOSITIONS DE CREME PHARMACEUTIQUE ET LEURS PROCEDES D'UTILISATION (PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE) | See Plans and Pricing |
European Patent Office | 2645993 | COMPOSITIONS DE CRÈME PHARMACEUTIQUE CONTENANT DE L'OXYMETAZOLINE (PHARMACEUTICAL CREAM COMPOSITIONS COMPRISING OXYMETAZOLINE) | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |